NCT03446547 - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions

NSCLC, Stage I

Interventions

DRUG

Durvalumab

durvalumab 1500 mg i.v. every fourth week for 12 months

Trial Locations (15)

RECRUITING

Helsinki, Helsinki

RECRUITING

Dept of Oncology, Tampere

RECRUITING

Turku, Turku

RECRUITING

Dept of Oncology, Vaasa

RECRUITING

Ålesund, Ålesund

RECRUITING

Dept of Oncology, Oslo

RECRUITING

Dept of pulmonary medicine, Tromsø

RECRUITING

Dept of Oncology, Trondheim

RECRUITING

Dept of pulmonary medicine, Gävle

RECRUITING

Dept. of Oncology, Gothenburg

RECRUITING

Dept of pulmonary medicine, Linköping

RECRUITING

Sunderbyn, Luleå

RECRUITING

Dept of pulmonary medicine, Lund

RECRUITING

Dept of Oncology, Stockholm

RECRUITING

Dept. of Oncology, Umeå